L C Hartmann

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. doi request reprint Understanding the Premalignant Potential of Atypical Hyperplasia through Its Natural History: A Longitudinal Cohort Study
    Lynn C Hartmann
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905
    Cancer Prev Res (Phila) 7:211-7. 2014
  2. pmc Mammary involution and breast cancer risk: transgenic models and clinical studies
    Derek C Radisky
    Department of Cancer Biology, Mayo Clinic, Jacksonville, FL 32224, USA
    J Mammary Gland Biol Neoplasia 14:181-91. 2009
  3. pmc Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancer
    Kristin L White
    Mayo Clinic College of Medicine, Rochester, MN, USA
    BMC Cancer 9:170. 2009
  4. ncbi request reprint Management of cancer pain. Safe, adequate analgesia to improve quality of life
    L C Hartmann
    Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Postgrad Med 107:267-72, 275-6. 2000
  5. ncbi request reprint Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy
    Lynn C Hartmann
    Mayo Clinic Cancer Center, 200 First Street Southwest, Rochester, MN 55905, USA
    Clin Cancer Res 11:2149-55. 2005
  6. ncbi request reprint Unrealistic expectations
    Lynn C Hartmann
    J Clin Oncol 23:4231-2; discussion 4233-4. 2005
  7. ncbi request reprint Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers
    L C Hartmann
    Division of Medical Oncology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    J Natl Cancer Inst 93:1633-7. 2001
  8. ncbi request reprint Genetic analysis of early- versus late-stage ovarian tumors
    V Shridhar
    Department of Experimental Pathology, Division of Laboratory Medicine, The Mayo Clinic and Foundation, 200 First Street SW, Rochester, Minnesota 55905, USA
    Cancer Res 61:5895-904. 2001
  9. ncbi request reprint Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer
    S K McDonnell
    Division of Medical Oncology, Mayo Clinic Cancer Center, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 19:3938-43. 2001
  10. ncbi request reprint Cigarette smoking increases risk for breast cancer in high-risk breast cancer families
    F J Couch
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Epidemiol Biomarkers Prev 10:327-32. 2001

Detail Information

Publications65

  1. doi request reprint Understanding the Premalignant Potential of Atypical Hyperplasia through Its Natural History: A Longitudinal Cohort Study
    Lynn C Hartmann
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905
    Cancer Prev Res (Phila) 7:211-7. 2014
    ..ADH and ALH behave similarly in terms of later breast cancer endpoints. Cancer Prev Res; 7(2); 211-7. ©2014 AACR. ..
  2. pmc Mammary involution and breast cancer risk: transgenic models and clinical studies
    Derek C Radisky
    Department of Cancer Biology, Mayo Clinic, Jacksonville, FL 32224, USA
    J Mammary Gland Biol Neoplasia 14:181-91. 2009
    ..By contrast, new human studies show that completion of lobular involution protects against subsequent breast cancer incidence...
  3. pmc Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancer
    Kristin L White
    Mayo Clinic College of Medicine, Rochester, MN, USA
    BMC Cancer 9:170. 2009
    ..Inhibitors of kappaB (IkappaB) prevent NF-kappaB activation by sequestering NF-kappaB proteins in the cytoplasm until IkappaB proteins are phosphorylated and degraded...
  4. ncbi request reprint Management of cancer pain. Safe, adequate analgesia to improve quality of life
    L C Hartmann
    Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Postgrad Med 107:267-72, 275-6. 2000
    ....
  5. ncbi request reprint Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy
    Lynn C Hartmann
    Mayo Clinic Cancer Center, 200 First Street Southwest, Rochester, MN 55905, USA
    Clin Cancer Res 11:2149-55. 2005
    ..We hypothesized that differences in gene expression before treatment could distinguish patients with short versus long time to recurrence after administration of platinum-paclitaxel combination chemotherapy...
  6. ncbi request reprint Unrealistic expectations
    Lynn C Hartmann
    J Clin Oncol 23:4231-2; discussion 4233-4. 2005
  7. ncbi request reprint Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers
    L C Hartmann
    Division of Medical Oncology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    J Natl Cancer Inst 93:1633-7. 2001
    ..We examined the association between bilateral prophylactic mastectomy and breast cancer risk in women at high risk for breast cancer who also had mutations in BRCA1 and BRCA2 genes...
  8. ncbi request reprint Genetic analysis of early- versus late-stage ovarian tumors
    V Shridhar
    Department of Experimental Pathology, Division of Laboratory Medicine, The Mayo Clinic and Foundation, 200 First Street SW, Rochester, Minnesota 55905, USA
    Cancer Res 61:5895-904. 2001
    ..However, differences observed at the genomic level suggest differences between the early- and late-stage tumors and provide support for a progression model for ovarian cancer development...
  9. ncbi request reprint Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer
    S K McDonnell
    Division of Medical Oncology, Mayo Clinic Cancer Center, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 19:3938-43. 2001
    ..6% to 99.5%). CONCLUSION: The incidence of contralateral breast cancer seems to be reduced significantly after contralateral prophylactic mastectomy in women with a personal and family history of breast cancer...
  10. ncbi request reprint Cigarette smoking increases risk for breast cancer in high-risk breast cancer families
    F J Couch
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Epidemiol Biomarkers Prev 10:327-32. 2001
    ..8-3.2). These results suggest that smoking may increase risk for breast cancer in families with multiple cases of breast or ovarian cancer, especially those with the strongest apparent familial predisposition...
  11. ncbi request reprint Association of Peutz-Jeghers-like mucocutaneous pigmentation with breast and gynecologic carcinomas in women
    L A Boardman
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Medicine (Baltimore) 79:293-8. 2000
    ..In particular, the relative risk for cancer in females with IMMP was significantly increased, as is true in females with PJS. However, LKB1 mutations did not contribute to the development of IMMP in the patients tested...
  12. doi request reprint Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner
    R Rattan
    Department of Experimental Pathology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Cell Mol Med 15:166-78. 2011
    ..Collectively, these results provide evidence on the role of metformin as an anti-proliferative therapeutic that can act through both AMPK-dependent as well as AMPK-independent pathways...
  13. pmc Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma
    M R Litzow
    Division of Hematology, Mayo Clinic Cancer Center, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Bone Marrow Transplant 45:490-7. 2010
    ..04). Topotecan can safely be dose escalated to 4.5 mg/m(2)/d in combination with CY, carboplatin and AHSCT. This trial is registered at ClinicalTrials.gov as NCT00652691...
  14. ncbi request reprint Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer
    V Shridhar
    Division of Experimental Pathology, Mayo Clinic Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Res 61:4258-65. 2001
    ....
  15. ncbi request reprint Breast cancer prevention trials
    D J Rhodes
    Division of General Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Oncol Rep 2:558-65. 2000
    ..Until the results of this trial are available, it is premature to use raloxifene for primary breast cancer prevention...
  16. pmc Folate receptor alpha as a tumor target in epithelial ovarian cancer
    Kimberly R Kalli
    Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Gynecol Oncol 108:619-26. 2008
    ..The goal of this study is to improve historical data that lack specific information about FRalpha expression in rare histological subtypes, primary disease versus metastatic foci, and recurrent disease...
  17. pmc An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer
    Kimberly R Kalli
    Departments of Oncology, Immunology, and Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA
    Cancer Res 68:4893-901. 2008
    ..All four peptides are naturally processed and presented to CD4 T-cells. The degenerate pool of peptides covers nearly 80% of patients and may be useful for augmenting CD4 T-cell immunity in patients undergoing immunization...
  18. ncbi request reprint Benign breast disease and the risk of breast cancer
    Lynn C Hartmann
    Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    N Engl J Med 353:229-37. 2005
    ..Benign breast disease is an important risk factor for breast cancer. We studied a large group of women with benign breast disease to obtain reliable estimates of this risk...
  19. ncbi request reprint Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance
    Marlene H Frost
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 23:7849-56. 2005
    ..The purpose of this research is to evaluate women's long-term satisfaction with CPM, factors influencing satisfaction, and psychological and social function after CPM...
  20. ncbi request reprint Independent test set performance in the prediction of early relapse in ovarian cancer with gene expression profiles
    Frank De Smet
    Clin Cancer Res 11:7958-9; author reply 7959. 2005
  21. ncbi request reprint An analysis of breast cancer risk in women with single, multiple, and atypical papilloma
    Jason T Lewis
    Division of Anatomic Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Surg Pathol 30:665-72. 2006
    ..The presence of papilloma in, or associated with, atypia does not modify the risk connotation of ADH/ALH overall. MP constitutes a proliferative breast disease subset having unique clinical and biologic behavior...
  22. pmc Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity
    Jeremy Chien
    Department of Laboratory Medicine and Experimental Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA, Medical Oncology Unit and Department of Histopathology, San Salvatore Hospital, Pesaro, Italy
    J Clin Invest 116:1994-2004. 2006
    ....
  23. ncbi request reprint T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer
    Keith L Knutson
    Department of Immunology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Clin Oncol 24:4254-61. 2006
    ..A candidate antigen is the folate receptor alpha (FRalpha), which is overexpressed in breast and ovarian cancers. Our goal in this study was to attain a better understanding of the extent of endogenous FRalpha immunity...
  24. ncbi request reprint The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer
    Kosei Hasegawa
    Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Clin Cancer Res 12:6170-8. 2006
    ..To minimize potential toxicity due to measles virus-associated immunosuppression and infection of nontarget tissues, we sought to develop an ovarian cancer exclusive fully retargeted measles virus...
  25. ncbi request reprint Age-related lobular involution and risk of breast cancer
    Tia R Milanese
    Mayo Medical School, Rochester, MN 55905, USA
    J Natl Cancer Inst 98:1600-7. 2006
    ..As women age, the lobules in their breasts undergo involution or regression. We investigated whether lobular involution in women with benign breast disease was associated with subsequent breast cancer risk...
  26. ncbi request reprint Benign breast disease: emerging findings in a diverse population
    Lynn C Hartmann
    Breast J 13:113-4. 2007
  27. ncbi request reprint Folate receptor overexpression is associated with poor outcome in breast cancer
    Lynn C Hartmann
    Division of Medical Oncology, Mayo Clinic Cancer Center and Mayo Clinic College of Medicine, Rochester, MN
    Int J Cancer 121:938-42. 2007
    ..001. Our work requires validation in a larger cohort, but supports the possibility of using folate receptor-targeted approaches in the management of breast cancer...
  28. doi request reprint Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer
    Daniel W Visscher
    Department of Surgical Pathology, University of Michigan, Ann Arbor, MI, USA
    J Natl Cancer Inst 100:421-7. 2008
    ..Atypical hyperplasia in breast tissue, although benign, is associated with a high risk of breast cancer. We investigated whether COX-2 overexpression in atypical hyperplasia is associated with the risk of subsequent breast cancer...
  29. ncbi request reprint Stratification of breast cancer risk in women with atypia: a Mayo cohort study
    Amy C Degnim
    Division of General Surgery, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Clin Oncol 25:2671-7. 2007
    ..Atypical hyperplasia is a well-recognized risk factor for breast cancer, conveying an approximately four-fold increased risk. Data regarding long-term absolute risk and factors for risk stratification are needed...
  30. ncbi request reprint Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer
    Jeremy R Chien
    Department of Experimental Pathology, Mayo Clinic, Rochester, Minnesota, USA
    J Cell Biochem 102:1117-29. 2007
    ..Finally, we will discuss advances and new challenges in the development of mouse model systems to investigate EOC precursor lesions, progression, metastasis, and chemoresistance...
  31. doi request reprint Breast cancer risk in women with radial scars in benign breast biopsies
    Jena C Berg
    Department of Laboratory Medicine and Pathology, Division of Anatomic Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Breast Cancer Res Treat 108:167-74. 2008
    ..We studied the relative risk of radial scar lesions in a large cohort of patients with benign breast disease (BBD)...
  32. ncbi request reprint Immunomagnetic diffractometry for detection of diagnostic serum markers
    Ghanashyam Acharya
    Birck Nanotechnology Center, Purdue University, West Lafayette, Indiana 47907, USA
    J Am Chem Soc 129:15824-9. 2007
    ..With this approach, a detection sensitivity of 700 fM (20 pg/mL) was achieved. The potential use of this approach in clinical diagnostics was demonstrated by measuring FR concentration in blood samples obtained from cancer patients...
  33. ncbi request reprint Elevated fibroblast growth factor 23 in women with malignant ovarian tumors
    Peter J Tebben
    Department of Pediatric and Adolescent Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Mayo Clin Proc 80:745-51. 2005
    ..To determine whether fibroblast growth factor 23 (FGF23) concentrations are altered in women with ovarian cancers in which FGF physiology is known to be abnormal...
  34. ncbi request reprint Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer
    Jeremy Chien
    Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic Foundation, 200 First Street, SW Rochester, MN 55905, USA
    Oncogene 24:5089-100. 2005
    ..These data implicate TCEAL7 as a cell death regulatory protein that is frequently inactivated in ovarian cancers, and suggest that it may function as a tumor suppressor...
  35. ncbi request reprint Reoperations after prophylactic mastectomy with or without implant reconstruction
    Sara M Zion
    New York Presbyterian Hospital, Weill Cornell Medical Center, New York, New York, USA
    Cancer 98:2152-60. 2003
    ..The authors characterized the unanticipated reoperations after prophylactic mastectomy, with or without implant reconstruction...
  36. ncbi request reprint Microsatellite instability in hereditary and sporadic breast cancers
    Camilo Adem
    1Division of Laboratory Genetics, Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Int J Cancer 107:580-2. 2003
    ..Mismatch repair gene mutations may be secondary random events in breast cancer progression...
  37. ncbi request reprint Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer
    Janos L Tanyi
    Departments of Molecular Therapeutics, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:3534-45. 2003
    ..Thus, the LPA-rich environment of the ovarian cancer cell in vivo and the subsequent effects of cellular pathophysiology may be a consequence of both increased LPA production and decreased LPA metabolism by ovarian cancer cells...
  38. ncbi request reprint Risk of breast cancer and breast cancer characteristics in women treated with supradiaphragmatic radiation for Hodgkin lymphoma: Mayo Clinic experience
    Dietlind L Wahner-Roedler
    Division of Area General Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:708-15. 2003
    ..To evaluate the overall risk of breast cancer and breast cancer characteristics in women given supradiaphragmatic radiation therapy for Hodgkin lymphoma...
  39. ncbi request reprint Her-2/neu expression in ovarian cancer: pre- and postexposure to platinum chemotherapy
    Prema P Peethambaram
    Mayo Clinic, Rochester, MN 55905, USA
    Gynecol Oncol 89:99-104. 2003
    ..Our objective was to determine if the level of Her-2/neu expression in advanced ovarian cancer changed after platinum-based chemotherapy...
  40. ncbi request reprint Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers
    Camilo Adem
    Division of Laboratory Genetics, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Cancer 97:1-11. 2003
    ....
  41. ncbi request reprint Long-term survival of patients with advanced/recurrent carcinoma of cervix and vagina after neoadjuvant treatment with methotrexate, vinblastine, doxorubicin, and cisplatin with or without the addition of molgramostim, and review of the literature
    Harry J Long
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Am J Clin Oncol 25:547-51. 2002
    ..Its progression-free survival and overall survival rates appear promising. These results need to be confirmed within a large randomized phase III clinical trial...
  42. ncbi request reprint Current status of prophylactic mastectomy
    Karthik Ghosh
    Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Oncology (Williston Park) 16:1319-25; discussion 1325, 1329-30, 1332. 2002
    ..It is also imperative that the woman be informed of alternative options for management, including chemoprevention, close surveillance, and prophylactic oophorectomy...
  43. ncbi request reprint Multimodal therapy including neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) for stage IIB to IV cervical cancer
    Sean C Dowdy
    Section of Gynecologic Surgery, Mayo Clinic, Rochester, MN 55905, USA
    Am J Obstet Gynecol 186:1167-73. 2002
    ....
  44. ncbi request reprint High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases
    Peter M Anderson
    Department of Pediatrics, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 20:189-96. 2002
    ..Because the dose-limiting toxicity of (153)Sm-EDTMP is thrombocytopenia, a dose-escalation trial using peripheral-blood progenitor cells (PBPCs) or marrow support was conducted to treat metastatic bone cancer...
  45. ncbi request reprint Stories of breast cancer through art
    Julie A Ponto
    Women s Cancer Program, Mayo Clinic Cancer Center, Rochester, MN, USA
    Oncol Nurs Forum 30:1007-13. 2003
    ..To describe the use of an art exhibit, created in response to breast cancer survivor stories, and additional supplementary activities to increase cancer awareness and provide support to those with cancer...
  46. ncbi request reprint Surgical risk reduction: prophylactic salpingo-oophorectomy and prophylactic mastectomy
    Sean C Dowdy
    Department of Obstetrics and Gynecology, Division of Gynecologic Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Obstet Gynecol 191:1113-23. 2004
    ..We also present data about the frequency of use and psychosocial impact of prophylactic surgery in this typically young group of women. Finally, we provide general treatment guidelines for the practicing clinician...
  47. ncbi request reprint Bilateral oophorectomy and breast cancer risk reduction among women with a family history
    Janet E Olson
    Health Science Research, Mayo Foundation, Rochester, MN 55905, USA
    Cancer Detect Prev 28:357-60. 2004
    ..We investigated whether removal of the ovaries is an appropriate risk reduction option for women at elevated risk of breast cancer based on family history of breast cancer...
  48. ncbi request reprint Pathophysiology and palliation of inoperable bowel obstruction in patients with ovarian cancer
    Aminah Jatoi
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Support Oncol 2:323-34; discussion 334-7. 2004
    ..This review discusses the general approach to patients with ovarian cancer and inoperable malignant bowel obstruction, with an emphasis on such palliative strategies...
  49. ncbi request reprint ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers
    Camilo Adem
    Division of Laboratory Genetics, Mayo Clinic and Foundation, Rochester, Minnesota, USA
    Genes Chromosomes Cancer 41:1-11. 2004
    ....
  50. ncbi request reprint Prophylactic mastectomy for BRCA1/2 carriers: progress and more questions
    Lynn C Hartmann
    J Clin Oncol 22:981-3. 2004
  51. ncbi request reprint Long-term follow-up of women with ovarian cancer after positive second-look laparotomy
    Sean C Dowdy
    Gynecologic Surgery, Mayo Clinic, Rochester, MN 55905, USA
    Gynecol Oncol 91:563-8. 2003
    ..The aim of this investigation was to determine whether these findings held true with extended follow-up and a larger patient cohort...
  52. ncbi request reprint Heterogeneous role of caspase-8 in fenretinide-induced apoptosis in epithelial ovarian carcinoma cell lines
    Kimberly R Kalli
    Endocrine Research Unit, Joseph 5 194, Mayo Clinic and Foundation, 200 First Street S W, Rochester, MN 55905, USA
    Mol Pharmacol 64:1434-43. 2003
    ..These results indicate that synthetic retinoids can use caspase-8 as an initiating caspase, but they also indicate unexpected heterogeneity in caspase activation pathways among closely related cell lines...
  53. ncbi request reprint MR elastography of breast cancer: preliminary results
    Alexia L McKnight
    Department of Radiology, Mayo Clinic, 200 First St, S W, Rochester, MN 55905, USA
    AJR Am J Roentgenol 178:1411-7. 2002
    ....
  54. ncbi request reprint A piece of my mind. The octogenarian's plan
    Lynn C Hartmann
    JAMA 293:15-6. 2005
  55. ncbi request reprint Breast biopsy utilization: a population-based study
    Karthik Ghosh
    Division of General Internal Medicine, Department of Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Arch Intern Med 165:1593-8. 2005
    ..However, scant data exist regarding the utilization of breast biopsies in the community population...
  56. ncbi request reprint Intraperitoneal therapy of ovarian cancer using an engineered measles virus
    Kah Whye Peng
    Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 62:4656-62. 2002
    ..Trackable recombinant measles viruses warrant further investigation for therapy of ovarian cancer...
  57. pmc Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor-specific fluorescent ligands
    Wei He
    Department of Chemistry, Purdue University, West Lafayette, IN 47906, USA
    Int J Cancer 123:1968-73. 2008
    ..Use of tumor-specific fluorescent ligands to label CTCs in peripheral blood can provide a simple, accurate and sensitive method for determining the number of cancer cells circulating in the bloodstream...
  58. ncbi request reprint Recreational physical activity and risk of postmenopausal breast cancer based on hormone receptor status
    Aditya Bardia
    Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Arch Intern Med 166:2478-83. 2006
    ..The objective of this study was to examine the association of physical activity with breast cancer incidence based on ER/PR status of the tumor...
  59. ncbi request reprint Estrogen bioactivation, genetic polymorphisms, and ovarian cancer
    Thomas A Sellers
    Division of Cancer Prevention and Control, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33602, USA
    Cancer Epidemiol Biomarkers Prev 14:2536-43. 2005
    ..015). Although preliminary, this study provides some support for the hypothesis that low-penetrance susceptibility alleles may influence risk of epithelial ovarian cancer...
  60. pmc Association of single nucleotide polymorphisms in glycosylation genes with risk of epithelial ovarian cancer
    Thomas A Sellers
    Division of Cancer Prevention and Control, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    Cancer Epidemiol Biomarkers Prev 17:397-404. 2008
    ..10 frequency; odds ratio, 0.07; P = 0.01) compared with the most common haplotype (0.39 frequency). These results suggest that genetic polymorphisms in the glycoslyation process may be novel risk factors for ovarian cancer...
  61. pmc Relative weight at age 12 and risk of postmenopausal breast cancer
    Aditya Bardia
    Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN 55905, USA
    Cancer Epidemiol Biomarkers Prev 17:374-8. 2008
    ....
  62. ncbi request reprint Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice
    B Lawrence Riggs
    Division of Endocrinology and Metabolism, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    N Engl J Med 348:618-29. 2003
  63. pmc In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometry
    Wei He
    Department of Chemistry, Purdue University, West Lafayette, IN 47907, USA
    Proc Natl Acad Sci U S A 104:11760-5. 2007
    ....
  64. ncbi request reprint Helping people cope with bereavement: an opportunity for health care providers to link Web-based resources across Minnesota
    Aminah Jatoi
    Department of Oncology, Mayo Clinic, Rochester, USA
    Minn Med 89:42-4. 2006
    ..It also suggests a need for health care institutions across the state to share information about their particular resources via the Internet with health care providers and patients...
  65. ncbi request reprint Current management strategies for ovarian cancer
    Giovanni D Aletti
    Division of Gynecologic Surgery, College of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:751-70. 2007
    ..In this review, we provide an overview of ovarian cancer with particular emphasis on recent advances in operative management and systemic therapies...

Research Grants9

  1. PROPHYLCTIC MASTECTOMY IN HEREDITARY BREAST CANCER
    Lynn Hartmann; Fiscal Year: 2002
    ..We will also define short- and long-term complications following PM. ..
  2. Paul Calabresi Program in Clinical-Translational Research at Mayo Clinic
    Lynn Hartmann; Fiscal Year: 2007
    ....
  3. Risk Prediction for Breast Cancer: A Tissue-Based Strategy
    Lynn Hartmann; Fiscal Year: 2009
    ..We will combine tissue-based histologic and biomarker information, with standard risk factor data, from a large cohort of women with benign breast biopsies to craft a comprehensive risk prediction model for breast cancer. ..
  4. Risk Prediction for Breast Cancer: A Tissue-Based Strategy
    Vernon Shane Pankratz; Fiscal Year: 2010
    ..We will combine tissue-based histologic and biomarker information, with standard risk factor data, from a large cohort of women with benign breast biopsies to craft a comprehensive risk prediction model for breast cancer. ..